Login to Your Account



Clinic Roundup


Friday, April 27, 2012
• CytRx Corp., of Los Angeles, began a Phase II trial of INNO-2006 for pancreatic ductual adenocarcinomas. The open-label trial will enroll up to 27 patients to receive IV INNO-206 once every three weeks for eight cycles. The trial will assess objective tumor response, with secondary endpoints of complete and partial response, stable disease at four months and progression-free survival.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription